>...PlGF inhibitors don't seem to be as effective as their more established rivals. Avastin and others do their job to such an extent that the body begins to produce other molecules that promote new blood vessel growth (angiogenesis), including PlGF.
This effectively 'rescues' the tumour from the effects of Avastin and can lead to some patients becoming resistant to the therapy. By working less well, TB-403 doesn't induce this rescue attempt and the developers hope patients won't become resistant to it.<
They may need to start with Avastin or another VEGF blocker, then switch to an anti-PIGF drug when Avastin resistance occurs, because blocking PIGF won't help the patient if their tumors thrive on VEGF alone. Still, presumably an anti-PIGF treatment would have far fewer potential side effects than anti-VEGF treatments, although like most chemotherapy or radiation treatments, a pregnant woman might want to avoid it.
Market Data 
Markets 
AI
